Sage Therapeutics says rare disease drug found to be safe in mid-stage study (updated)

Sage Therapeutics

11/06/2024 12:24

(Adds details on study in paragraph 2, shares in paragraph 3
and background in paragraph 4)
       June 11 (Reuters) - Sage Therapeutics  SAGE.O  said on
Tuesday its experimental drug was found to be safe and showed
some effect in patients with a rare, genetic neurological
condition called Huntington's disease in a part of a mid-stage
study.
    The company, however, said the study in Huntington's disease
patients was not designed to show a statistically significant
difference between the drug dalzanemdor and placebo.
    Shares of the company, which soared 80% initially, erased
those gains and were down 1.6% in volatile premarket trading.
        The news follows a mid-stage trial failure for the same
drug, in April when it was tested in patients with Parkinson's
disease.

 (Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh
Kuber)
 ((Sriparna.Roy@thomsonreuters.com;))